Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;14(1):17757.
doi: 10.1038/s41598-024-68470-z.

A methylation risk score for chronic kidney disease: a HyperGEN study

Affiliations

A methylation risk score for chronic kidney disease: a HyperGEN study

Alana C Jones et al. Sci Rep. .

Abstract

Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (CpG) sites, have been linked to kidney function and may have clinical utility in predicting the risk of CKD. Given the dynamic relationship between the epigenome, environment, and disease, AAs may be especially sensitive to environment-driven methylation alterations. Moreover, risk models incorporating CpG methylation have been shown to predict disease across multiple racial groups. In this study, we developed a methylation risk score (MRS) for CKD in cohorts of AAs. We selected nine CpG sites that were previously reported to be associated with estimated glomerular filtration rate (eGFR) in epigenome-wide association studies to construct a MRS in the Hypertension Genetic Epidemiology Network (HyperGEN). In logistic mixed models, the MRS was significantly associated with prevalent CKD and was robust to multiple sensitivity analyses, including CKD risk factors. There was modest replication in validation cohorts. In summary, we demonstrated that an eGFR-based CpG score is an independent predictor of prevalent CKD, suggesting that MRS should be further investigated for clinical utility in evaluating CKD risk and progression.

Keywords: Chronic kidney disease; Epigenetics; Methylation risk score; eGFR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study overview.
Figure 2
Figure 2
Distribution of optimized MRS in HyperGEN.
Figure 3
Figure 3
Forest plot of meta-analyzed MRS associations in validation cohorts. (A) Meta-analysis results for CKD associations in validation cohorts. (B) Meta-analysis results for eGFR associations in validation cohorts.

References

    1. Prevention, C. F. D. C. a. Chronic Kidney Disease in the United States, 2021. (Atlanta, GA, 2021).
    1. System, U. S. R. D. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).
    1. Laster, M., Shen, J. I. & Norris, K. C. Kidney disease among African Americans: A population perspective. Am. J. Kidney Dis.72, S3–S7. 10.1053/j.ajkd.2018.06.021 (2018). 10.1053/j.ajkd.2018.06.021 - DOI - PMC - PubMed
    1. Vart, P., van Zon, S. K. R., Gansevoort, R. T., Bultmann, U. & Reijneveld, S. A. SES, chronic kidney disease, and race in the U.S.: A systematic review and meta-analysis. Am. J. Prev. Med.53, 730–739. 10.1016/j.amepre.2017.06.036 (2017). 10.1016/j.amepre.2017.06.036 - DOI - PubMed
    1. Vart, P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988–2016. JAMA Netw. Open3, e207932. 10.1001/jamanetworkopen.2020.7932 (2020). 10.1001/jamanetworkopen.2020.7932 - DOI - PMC - PubMed